The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Circulating tumor cells (CTCs) in SWOG S1216: A phase 3 multicenter trial in metastatic hormone sensitive prostate cancer (mHSPC).
 
Amir Goldkorn
No Relationships to Disclose
 
Melissa Plets
No Relationships to Disclose
 
Neeraj Agarwal
Research Funding - amgen (Inst); Bayer (Inst); BN ImmunoTherapeutics (Inst); Bristol-Myers Squibb (Inst); Exelixis (Inst); GlaxoSmithKline (Inst); ImClone Systems (Inst); Medivation (Inst); Novartis (Inst); Pfizer (Inst); Rexahn Pharmaceuticals (Inst); Takeda (Inst); TRACON Pharma (Inst)
 
Maha Hussain
Consulting or Advisory Role - AstraZeneca; Essa; Johnson & Johnson; Synthon
Research Funding - Astellas Pharma (Inst); Bayer (Inst); Genentech (Inst); Medivation (Inst); Pfizer (Inst)
Patents, Royalties, Other Intellectual Property - TITLE: Dual Inhibition of MET and VEGF for the treatment of castration resistant prostate cancer and osteoblastic bone metastases. Applicant/Proprietor Exelexis, Inc. Application No/Patent No. 11764665.4- 1464 Application No/Pat; TITLE: METHOD OF TREATING CANCER Docket No: Serial Number: 224990/10-016P2/311733 61/481/671 Application Filed on: 5/2/2011; TITLE: SYSTEMS AND METHODS FOR TISSUE IMAGING, 3676 Our File: Serial Number: UM-14437/US-1/PRO 60/923,385 UM-14437/US-2/ORD 12/101,753
 
Primo Lara
Honoraria - Pfizer
Consulting or Advisory Role - Astex Pharmaceuticals; Clovis Oncology; Exelixis; Halozyme; Immunogen; Janssen; Lilly; LPath; Medivation; Novartis; Pfizer; Sanofi; Teva; US Diagnostic Services
Research Funding - Aragon Pharmaceuticals (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Heat Biologics (Inst); Janssen Biotech (Inst); Millennium (Inst); Oncogenex (Inst); Polaris (Inst)
 
Daniel A. Vaena
Research Funding - Acerta Pharma (Inst); Argos Therapeutics (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Exelixis (Inst); GlaxoSmithKline (Inst); Novartis (Inst); Roche/Genentech (Inst); Tekmira (Inst); TRACON Pharma (Inst)
 
Gary R. MacVicar
No Relationships to Disclose
 
Tony Crispino
No Relationships to Disclose
 
Andrea Lynne Harzstark
No Relationships to Disclose
 
Przemyslaw Twardowski
No Relationships to Disclose
 
Catherine M. Tangen
No Relationships to Disclose
 
Cory Michael Hugen
No Relationships to Disclose
 
Tong Xu
No Relationships to Disclose
 
Yucheng Xu
No Relationships to Disclose
 
Jacek K. Pinski
Stock and Other Ownership Interests - MDOracle; OncoNatural Solutions
Consulting or Advisory Role - Sandoz
Speakers' Bureau - Astellas Medivation; Bayer; Dendreon; Janssen
Patents, Royalties, Other Intellectual Property - OncoNatural Solutions
 
Sue A. Ingles
No Relationships to Disclose
 
Celestia S. Higano
Employment - Cell Therapeutics (I)
Leadership - Cell Therapeutics (I)
Stock and Other Ownership Interests - Cell Therapeutics (I)
Consulting or Advisory Role - AbbVie; Bayer; BHR Pharma; Dendreon; Ferring; Genentech; Johnson & Johnson; Medivation; Orion; Pfizer; Sanofi
Research Funding - Algeta/Bayer (Inst); Aragon Pharmaceuticals (Inst); AstraZeneca (Inst); Dendreon (Inst); Emergent BioSolutions (Inst); Exelixis (Inst); Genentech (Inst); Medivation (Inst); Millennium (Inst); Oncogenex (Inst); Sanofi (Inst); Teva (Inst)
Travel, Accommodations, Expenses - AbbVie; Amgen; Astellas Pharma; Bayer; Dendreon; Ferring; Genentech; Johnson & Johnson; Medivation; Ockham; Orion; Pfizer; Sanofi; Teva
 
Nicholas J. Vogelzang
Employment - US Oncology
Stock and Other Ownership Interests - Caris Life Sciences
Honoraria - Abbvie; Bavarian Nordic; Dava Oncology; Endocyte; Mannkind; UpToDate
Consulting or Advisory Role - Amgen; AVEO; BIND Biosciences; Cerulean Pharma; Janssen Biotech; Labceutics; Pfizer
Speakers' Bureau - Bayer; Caris MPI; Dendreon; Genentech/Roche; GlaxoSmithKline; Medivation; Millennium; Pfizer; Sanofi
Research Funding - Endocyte (Inst); Exelixis (Inst); GlaxoSmithKline (Inst); Parexel (Inst); Progenics (Inst); US Oncology (Inst); Viamet Pharmaceuticals (Inst)
Travel, Accommodations, Expenses - Bayer/Onyx; Celgene; Dendreon; Exelixis; Genentech/Roche; Novartis; Pfizer; US Oncology
 
Ian Murchie Thompson
Consulting or Advisory Role - Exosome diagnostics; Magforce
Patents, Royalties, Other Intellectual Property - I have been involved in the establishment of a new company - NanoTX Therapeutics to commercialize a novel therapy for glioblastoma for our cancer center. I am on the Board of Directors and it has intellectual property developed by our cancer center.; I have several patents with colleagues involving novel biomarkers for cancer and two devices for sexual dysfunction and urinary incontinence. No revenues at this time and our University IP office is working with industry to determine if these can be comme
 
David I. Quinn
Honoraria - Astellas Pharma; Bayer; Bristol-Myers Squibb; Dendreon; Fresenius Kabi; Genentech/Roche; Janssen Oncology; Medivation; Novartis; Pfizer
Consulting or Advisory Role - Algeta/Bayer; Astellas Pharma; Bristol-Myers Squibb; Dendreon; Genentech/Roche; Janssen Oncology; Medivation; Novartis; Pfizer
Research Funding - Genentech/Roche (Inst); GlaxoSmithKline (Inst); Millennium (Inst); Sanofi (Inst)
Expert Testimony - Medivation; Teva